Market Place
Sourcing Support
Prelude Therapeutics Presents Phase 1 Results of PRT2527 Study
11 Dec 2024 //
GLOBENEWSWIRE
Prelude to Participate in JMP Hematology & Oncology Summit
27 Nov 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Reports Q3 2024 Financials & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Presents SMARCA Degrader Data At Symposium
24 Oct 2024 //
GLOBENEWSWIRE
Prelude Announces Abstracts For EORTC-NCI-AACR Symposium
09 Oct 2024 //
GLOBENEWSWIRE
Prelude Therapeutics` PRT3789 Shows Promise In Phase 1 Trial
13 Sep 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Announces Abstract For ESMO Congress
09 Sep 2024 //
GLOBENEWSWIRE
Pathos AI Licenses PRT811 from Prelude Therapeutics
16 Aug 2024 //
CONTRACT PHARMA
Prelude Therapeutics Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Partners With Merck For Cancer Combination Study
09 Jul 2024 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
03 Jun 2024 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
09 May 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Q1 2024 Results And Corporate Update
07 May 2024 //
GLOBENEWSWIRE
Prelude Showcases Discovery Engine at AACR Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR
05 Mar 2024 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
29 Feb 2024 //
GLOBENEWSWIRE
Prelude Reports Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Announces $25 Million Private Placement
11 Dec 2023 //
GLOBENEWSWIRE
Prelude Therapeutics and AbCellera Enter Partnership
01 Nov 2023 //
GLOBENEWSWIRE
Prelude Announces Strategic Pipeline Progress and Updates
01 Nov 2023 //
GLOBENEWSWIRE
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR
14 Oct 2023 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate in Three Healthcare Investor in September
29 Aug 2023 //
GLOBENEWSWIRE
Prelude Therapeutics Announces Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Prelude Therapeutics Announces Pricing of Public Offering
18 May 2023 //
GLOBENEWSWIRE
Prelude Therapeutics Announces Launch of Proposed Public Offering
17 May 2023 //
GLOBENEWSWIRE
Prelude Therapeutics Announces 1Q 2023 FYR and Operations Update
08 May 2023 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences May
27 Apr 2023 //
GLOBENEWSWIRE
Prelude to Present at American Association for Cancer Research 2023 Conference
11 Apr 2023 //
GLOBENEWSWIRE
Prelude Announces Trial Collaboration with BeiGene to Evaluate PRT2527
15 Mar 2023 //
GLOBENEWSWIRE
Prelude Reports Full Year 2022 Financial Results and Provides Corporate Update
15 Mar 2023 //
GLOBENEWSWIRE
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
01 Mar 2023 //
GLOBENEWSWIRE
Prelude To Participate in Two Upcoming Healthcare Investor Conferences
09 Feb 2023 //
GLOBENEWSWIRE
Prelude Therapeutics Announces 3Q 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
3 more biotechs look to cull, partner assets
14 Nov 2022 //
FIERCEBIOTECH
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789
18 Oct 2022 //
GLOBENEWSWIRE
Prelude Therapeutics To Participate in Upcoming HC Wainwright & Morgan Stanley
06 Sep 2022 //
GLOBENEWSWIRE
Prelude Therapeutics Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Prelude Tx Reports FY 2021 Financial Results
16 Mar 2022 //
GLOBENEWSWIRE
Prelude Tx to Participate at the Barclays 2022 Global Healthcare Conference
11 Mar 2022 //
GLOBENEWSWIRE
Jane Huang, M.D., Joins Prelude Tx as President and CMO
09 Mar 2022 //
GLOBENEWSWIRE
Prelude Tx to Provide Update Present New PC Data
09 Mar 2022 //
GLOBENEWSWIRE
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Conference
11 Feb 2022 //
GLOBENEWSWIRE
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI
23 Nov 2021 //
GLOBENEWSWIRE
Prelude Announces Q3 2021 Financial Results and Operations Update
12 Nov 2021 //
GLOBENEWSWIRE
AMA Grants PreludeDx a CPT PLA Code for Proprietary DCISionRT Test
10 Nov 2021 //
BIOSPACE
Prelude Therapeutics Announces IND Clearance for PRT2527
08 Nov 2021 //
GLOBENEWSWIRE
DarwinHealth Collaborates with Prelude Therapeutics to Develop New Biomarkers
13 Oct 2021 //
PRNEWSWIRE
DarwinHealth Collaborates with Prelude to Develop Novel Biomarkers for Oncology
12 Oct 2021 //
PRNEWSWIRE
Dosing underway in Prelude Therapeutics` early-stage PRT1419 trial
29 Sep 2020 //
SEEKING ALPHA
Prelude Therapeutics Finalizes IPO Terms
21 Sep 2020 //
SEEKING ALPHA
Oncology biotech Prelude Therapeutics sets terms for $150 million IPO
21 Sep 2020 //
NASDAQ
